Elaine Siegfried, MD: There’s tremendous work going on, and a lot of it is driven by investment from pharmaceutical companies in creating better treatments. Prior to very recently we had a handful of ...
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the inflammatory mechanisms of atopic dermatitis and risk of comorbidities in affected patients. Can you ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...
A critical narrative review finds that heat-sensitive itch in atopic dermatitis involves plausible links among skin barriers, ...
The burden of atopic dermatitis (AD) -- for patients, their families, and society -- is vast and increasing. AD affects approximately 10% to 30% of children and 2% to 10% of adults in developed ...
Access resources to help you promote the specialty in your community and beyond.
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, will present new data and insights in moderate-to-severe atopic dermatitis and chronic hand eczema at the ...
Efficacy of the investigational drug lebrikizumab is maintained in patients with moderate to severe atopic dermatitis for at least 1 year, according to new results from the phase 3 ADvocate1 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results